Core Insights - A team from Beihang University has developed a flexible implantable bioelectronic device called POCKET, which allows for personalized drug delivery and gene transfection by conforming to the complex shapes of organs [1][2] - The device addresses a significant clinical issue regarding hereditary ovarian gene mutations, providing a safer alternative to traditional gene therapy methods that pose risks to sensitive organs [1][2] Group 1 - The POCKET device utilizes electroporation, a physical method that opens cell membranes using electric fields, overcoming limitations of traditional devices that cannot conform to the irregular surfaces of organs [2] - The research team introduced the "organ-customized paper-cut conformal theory," establishing a quantitative relationship between geometric parameters and organ curvature, enabling the design of highly conformal patches for various organs [2] - The device has been validated in multiple animal models and ex vivo human tissues, offering a new tool for precise treatment of ovarian cancer prevention and organ damage repair [2] Group 2 - A high-tech company has been established based on this core technology, having completed multiple rounds of financing [3] - The first product, "Ultra-NEP," has been applied in the field of skin health, with plans to expand its applications in medical-grade devices [3]

Core Viewpoint - The article discusses a significant breakthrough in drug delivery technology, specifically through the development of a flexible, implantable bioelectronic device called POCKET, which allows for precise and efficient drug delivery to complex organ surfaces, addressing long-standing issues in traditional drug delivery methods [2][3]. Research Background - The research originated from a clinical challenge faced by doctors regarding hereditary ovarian gene mutations, where traditional gene therapy methods pose risks to reproductive cells. The team shifted focus to a physical method called electroporation to deliver therapeutic agents safely to ovarian surface cells without affecting the eggs [7]. Breakthrough Innovation - The research team drew inspiration from traditional paper-cutting art to create a "customized organ conformal kirigami theory," establishing a quantitative relationship between geometric parameters of the kirigami structure and the curvature of organs, enabling the design of patches that achieve over 95% coverage on organ surfaces [9]. Device Design and Functionality - The POCKET device features a four-layer functional design, including a nanopore array film for direct tissue contact, a hydrogel drug-loading layer, a silver nanowire electrode layer for electric field distribution, and a flexible substrate layer. This design allows for high conformability and large-area adhesion to various organ surfaces [12]. Efficacy Validation 1: Ovarian Cancer Prevention - In animal models, POCKET successfully delivered functional BRCA1 plasmids to ovarian surface cells, significantly reducing cancer risk without affecting reproductive cells. This approach restored ovarian hormone secretion and fertility, providing a viable alternative to surgical removal for women with cancer risk mutations [15]. Efficacy Validation 2: Organ Damage Repair - In kidney transplant scenarios, POCKET was used to deliver anti-inflammatory drugs locally, showing significant improvement in tubular repair and kidney function while avoiding systemic side effects associated with oral medications, highlighting its advantages in chronic disease management [19]. Technology Translation and Clinical Application - The POCKET platform offers new tools for precise treatment of ovarian cancer prevention and organ damage repair, integrating flexible electronics and micro-nano processing for effective control and long-term operation. The technology has progressed from laboratory to industry, with a high-tech company already established and the first product, Ultra-NEP, applied in skin health [22][24].

Domestic Investment - Daimeng Robotics completed a financing round of over 100 million yuan, focusing on high-resolution multi-modal tactile perception and intelligent solutions for various industries [1] - Zhirun Medical announced the completion of over 300 million yuan in Series A financing, aimed at advancing brain-machine interface technology for precise diagnosis of neurological diseases [2] - Leju Technology completed a B++ round of financing, with Kunlun Capital as the sole investor, marking the successful conclusion of its B round series [3][4] - Ronghe Yuanchu received B round financing from Guokun Investment, CIMC Group, and Yuanxin Fund, focusing on large-scale energy storage systems [5] - Feidu Technology completed several million yuan in strategic financing, developing a digital twin platform for various smart industries [6] - Xinghua Chip received an investment of 15 million yuan from Huitong Energy, increasing its registered capital [7] - Siweibo secured several million yuan in B round investment from Shenzhen Jiadao Green Low Carbon Investment Fund, focusing on agricultural biotechnology [8] - Guangdong Jianke went public on the Shenzhen Stock Exchange, raising 687 million yuan through the issuance of 105 million shares at 6.56 yuan each [9] - Ruimo Environmental completed a new round of financing led by Ingka Investments, focusing on recycled plastics [10] - Yongzhi Semiconductor received investment from Yida Capital to enhance its product development and capacity [11] - Lanyi Aviation completed several million yuan in Pre-A round financing, focusing on eVTOL aircraft development [12] Foreign Investment - HackQuest secured $4.1 million in Pre-A round financing, focusing on Web3 education [13] - HYLENR received $3 million in Pre-A round financing, developing low-energy nuclear reaction technology [14] - Chowdeck completed $9 million in Series A financing, focusing on local food delivery in Nigeria and Ghana [15] - FORT raised $18.9 million in Series B financing, developing a network security management platform [16] - Equillium announced up to $50 million in strategic investment for its autoimmune disease treatments [17] - Nanotein secured $3 million in strategic investment for its cell therapy products [18] - Tahoe Therapeutics completed $30 million in financing, focusing on AI-driven human cell models for drug design [19] - SetPoint Medical raised $115 million in Series D financing for its bioelectronic medicine platform [20] - August Health announced $29 million in Series B financing for its modern nursing care platform [21] IPO Queue - Jiaxin International submitted post-hearing materials for its tungsten mining project [22] - Koma Materials passed the review meeting, focusing on automotive clutch plate production [23] - Hongyuan Co. publicly offered shares, specializing in high-end transformer electromagnetic wire production [24]